These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31064846)

  • 1. A PolH Transcript with a Short 3'UTR Enhances PolH Expression and Mediates Cisplatin Resistance.
    Zhang J; Sun W; Ren C; Kong X; Yan W; Chen X
    Cancer Res; 2019 Jul; 79(14):3714-3724. PubMed ID: 31064846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
    Li QQ; Xie YK; Wu Y; Li LL; Liu Y; Miao XB; Liu QZ; Yao KT; Xiao GH
    Oncotarget; 2017 Feb; 8(7):12067-12080. PubMed ID: 28076844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29.
    Yang Z; Liu C; Wu H; Xie Y; Gao H; Zhang X
    BMC Cancer; 2019 Oct; 19(1):948. PubMed ID: 31615563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
    Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
    BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells.
    Hao GJ; Hao HJ; Ding YH; Wen H; Li XF; Wang QR; Zhang BB
    FEBS Lett; 2017 Feb; 591(4):636-645. PubMed ID: 28117895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
    Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
    Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating
    Hu Y; Cui J; Jin L; Su Y; Zhang X
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNA TUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta.
    Sonobe R; Yang P; Suzuki MM; Shinjo K; Iijima K; Nishiyama N; Miyata K; Kataoka K; Kajiyama H; Kondo Y
    Cancer Sci; 2024 Jun; 115(6):1910-1923. PubMed ID: 38558246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA‑10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells.
    Lin CC; Liao WT; Yang TY; Lu HJ; Hsu SL; Wu CC
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34165168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
    Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
    J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
    Sui C; Meng F; Li Y; Jiang Y
    J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
    Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
    Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian cancer.
    Marjamaa A; Gibbs B; Kotrba C; Masamha CP
    Sci Rep; 2023 Oct; 13(1):17476. PubMed ID: 37838788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival.
    Dai CH; Chen P; Li J; Lan T; Chen YC; Qian H; Chen K; Li MY
    Oncotarget; 2016 Oct; 7(40):65157-65170. PubMed ID: 27533083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CPSF6-mediated XBP1 3'UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma.
    Zhu C; Xie Y; Li Q; Zhang Z; Chen J; Zhang K; Xia X; Yu D; Chen D; Yu Z; Chen J
    Drug Resist Updat; 2023 May; 68():100933. PubMed ID: 36821972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
    Jiang P; Wu X; Wang X; Huang W; Feng Q
    Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.